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ABSTRACT

An isolated polynucleotide molecule includes a DNA
sequence encoding an infectious RNA molecule encoding a
modi?ed live viral strain of an Equine arteritis virus, Wherein
the DNA sequence is SEQ ID NO:1 or a degenerate variant
thereof. Also provided are transformed or transfected host

cells including that sequence, vectors including the sequence,
and isolated infectious RNA molecules encoded by the
sequence. Further, a modi?ed DNA sequence encoding an
infectious RNA molecule encoding a modi?ed live viral
strain of an Equine arteritis virus is provided Wherein the
DNA sequence is SEQ ID NO:2 or a degenerate variant

thereof, including a silent point mutation alloWing distin
guishing the modi?ed sequence from the parent and other
strains of Equine arteritis virus.

Balasuriya et al (Journal of General Virology, 2007. vol. 88, pp.

918-924).*

9 Claims, 2 Drawing Sheets
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INFECTIOUS CDNA CLONE OF THE
MODIFIED LIVE VIRUS VACCINE STRAIN

tion. One of the major concerns is the safety of the current
MLV vaccine in pregnant mares, in particular the ability of the
attenuated virus to cross the placenta and infects the unborn
foal. The vaccine is only recommended for use in stallions

OF EQUINE ARTERITIS VIRUS

This utility patent application claims the bene?t of priority

and nonpregnant mares. It is not recommended for use in

in US. Provisional Patent Application Ser. No. 61/156,595
?led on Mar. 2, 2009, the entirety of the disclosure of Which

pregnant mares, especially during the last tWo months of
gestation, or in foals less than 6 Weeks of age, unless they are
at high risk of natural exposure. Furthermore, horses that are
vaccinated With the current MLV cannot be distinguished

is incorporated herein by reference.
TECHNICAL FIELD

from naturally infected animals. FolloWing the recent multi

The present invention relates to an infectious clone of the

state EVA occurrence in the United States there is a strong

modi?ed live virus (MLV) vaccine strain of Equine arteritis

industry demand for a marker vaccine to distinguish vacci
nated animals from the naturally infected animals, as Well as
to develop a MLV vaccine that is totally safe for use in

Virus (EAV). In particular, the invention relates to an infec
tious cDNA clone of the MLV vaccine strain allowing gen
eration of full length, infectious transcripts of MLV EAV. Use
of the functional, infectious recombinant virion of EAV
derived from an attenuated vaccine strain in marker vaccines,

pregnant mares. Thus, there remains a need in the art for novel
means for control of outbreaks of EAV. The advent of recom

binant DNA technology has helped to develop neW genera
tion vaccines against a number of veterinary pathogens.

companion diagnostic tests, and the like is contemplated.
BACKGROUND OF THE INVENTION

Equine arteritis virus (EAV) is a member of the genus

20

Arlerivirus, family Arteriviridae in the order Nidovirales (Ca
vanagh, 1997), and is the causative agent of equine viral
arteritis (EVA) of horses (Doll et al., 1957a). Outbreaks of
EVA are characterized by any combination of systemic illness
of adult horses, abortion of pregnant mares, interstitial pneu
monia of young foals and persistent infection of stallions

SUMMARY OF THE INVENTION

To solve the aforementioned problems, there is provided an
isolated polynucleotide molecule comprising a DNA
25

(Doll et al., 1957a; Doll et al., 1957b; Golnik et al., 1981;
Timoney et al. 1986; Timoney et al., 1987; Timoncy et al.,
1992; Carman et al., 1988; Vaala et al., 1992; Del Piero et al.,
1995; Del Piero et al., 1997). EAV is horizontally transmitted
either by aerosol during outbreaks of EVA or venerally via the
breeding of an infected stallion to susceptible mares, and
vertically through congenital infection of foals born to mares
infected late in gestation (Timoney et al., 1987; Timoney et

al., 1992; Vaala et al., 1992; Timoney and McCollum, 1993;
Glaser et al., 1996).

30

ing the polynucleotide molecule are provided. Still further, an

35

source of infection in some outbreaks (Collins et al. 1987;

degenerate variant thereof. In this embodiment, a silent point

mutation is introduced, alloWing recognition and distinguish
ing the sequence from the parent strain Equine arteritis virus
or other strains of the virus. Vectors, host cells transfected

testosterone-dependent (Timoney and McCollum, 1993). It
Was recently shoWn that EAV behaves as a quasi-species
45

These and other embodiments, aspects, advantages, and

(Hedges et al., 1999).

features of the present invention Will be set forth in the

The EAV genome is 12.7 kb and contains 5' and 3' untrans

description Which folloWs, and in part Will become apparent
50

to those of ordinary skill in the art by reference to the folloW

ing description of the invention and referenced draWings or by
practice of the invention. The aspects, advantages, and fea

pp1ab; (de Vries et al., 1997; Snijder and Spaan, 2006;
Snijder and Meulenberg, 1998)], and the remaining seven

tures of the invention are realiZed and attained by means of the

instrumentalities, procedures, and combinations particularly
55

pointed out in the appended claims. Various patent and non
patent citations are discussed herein. Unless otherWise indi

cated, any such citations are speci?cally incorporated by ref
erence in their entirety into the present disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
60

The accompanying draWings incorporated in and forming
a part of the speci?cation, illustrate several aspects of the
present invention, and together With the description serve to
explain the principles of the invention. In the draWings:

Prevention and control of EVA in North America is
achieved by vaccination of horses With the modi?ed live virus

vaccine strain of EAV (ARVAC®, Fort DodgeAnimal Health;
Moore, 1986). Although the current modi?ed live virus
(MLV) vaccine against EVA is safe and ef?cacious, there is

With the polynucleotide molecule, and infectious RNA mol
ecules encoded by the polynucleotide molecule are provided
also.

emergence of novel genotypic and phenotypic viral variants

GP3 (3642 kDa), GP4 (28 kDa) and GP5 (30-44 kDa), respec
tively encoded by ORFs 2b, 3, 4, and 5, tWo unglycosylated
membrane proteins E (8 kDa) and M (17 kDa) encoded by
ORFs 2a and 6, and the phosphorylated nucleocapsid protein
N (14 kDa) encoded by ORF7 (de Vries et al., 1992; Snijder
et al., 1999; Wieringa et al, 2002).

isolated infectious RNA molecule encoded by the isolated
polynucleotide molecule is provided, Which encodes a modi
?ed live virus vaccine strain of the Equine arteritis virus.
In another aspect, there is provided an isolated polynucle
otide molecule comprising a DNA sequence Which encodes
an infectious RNA molecule encoding an Equine arteritis
virus, Wherein the DNA sequence is SEQ TD NO:2 or a

an important role in perpetuation and sexual dissemination of
EAV. The persistence of EAV in the male reproductive tract is

ORFs (2a, 2b and 3-7) encode structural proteins of the virus.
These include four membrane glycoproteins GP2 (25 kDa),

polynucleotide sequence is SEQ ID NO:1 or a degenerate

variant thereof. Vectors, including plasmid vectors, compris

Timoney and McCollum, 1988; Timoney and McCollum,
1993). The persistently infected carrier stallion clearly plays

lated regions and nine functional open reading frames [ORFs;
(Snijder and Meulenberg, 1998. Snijder et al., 1999)]. ORFs
1a and 1b encode tWo replicase polyproteins [pp1a and

sequence Which encodes an infectious RNA molecule encod
ing a modi?ed live virus vaccine strain of an Equine arteritis
virus. That polynucleotide sequence is derived from an

Equine arteritis virus modi?ed live virus vaccine strain (AR
VAC®, Fort Dodge Animal Health). In one embodiment, the

Dissemination of EAV by fomites such as vehicles,
tWitches, arti?cial vaginas and shanks can be an important

during persistent infection of carrier stallions, With regular

These include live-vectored vaccines, gene deletion mutants
and DNA vaccines.

FIG. 1 presents a schematic in How diagram form of a
65

cloning strategy for constructing a full-length infectious

resistance to using it in horses in many countries (eg Euro

cDNA clone of the Equine arteritis virus modi?ed live vac

pean Union) regardless of the seroprevalence of EAV infec

cine strain (ARVAC®); and

US 8,012,735 B2
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FIG. 2 shows immuno?uorescent staining of BHK-21 cells
transfected with in vitro transcribed RNA from the cDNA
clone shown in FIG. 1.

With reference to FIG. 1, in step 1 a shuttle vector

pBluEAVrVBSQihoI-EcoRV) was constructed by replacing
the fragment XhoI-EcoRV of the plasmid pBlu2SKP with the
fragment XhoI-EcoRV of the full-length clone pEAVrVBS.
Next (step 2), the fragment AB was digested with restriction

DETAILED DESCRIPTION OF THE
ILLUSTRATED EMBODIMENTS

enZymes XbaI and EcoRV and then cloned into the shuttle
vector pBluEAVrVBS(XhoI-EcoRV) which was also cut
with the same restriction enZymes, to obtain the recombinant

In the following detailed description of the illustrated
embodiments, reference is made to the accompanying draw
ings that form a part hereof, and in which is shown by way of
illustration, speci?c embodiments in which the invention may

plasmid pBluEAVMLV(XhoI-EcoRV). In step 3, the plasmid
pBluEAVMLVQihoI-EcoRV) was digested with restriction
enZymes XhoI and EcoRV and then cloned into the full
length clone pEAVrVBS which was also cut with the same
restriction enZymes, to obtain the recombinant plasmid

be practiced. These embodiments are described in su?icient
detail to enable those skilled in the art to practice the inven
tion. Also, it is to be understood that other embodiments may
be utiliZed and that process, reagent, software, and/or other

pEAVrVBSMLV(XhoI-EcoRV).
The fragment GH was digested (step 4) with restriction
enZymes BamHI and XhoI and then cloned into the plasmid

changes may be made without departing from the scope of the
present invention.

pEAVrVBSMLV @(hoI-EcoRV) which was also digested
with the same restriction enZymes, to obtain the recombinant

plasmid

EXAMPLE 1

FIG. 1 shows in ?ow diagram the strategy employed for

20

pEAVrVBSMLVQ(hoI-EcoRV&BamHI-Xhol).

Following, (step 5) the fragment EF was digested with restric
tion enZymes BlnI and BamHI and then cloned into the plas

construction of a full-length infectious cDNA clone of EAV

mid pEAVrVBSMLVQ(hoI-EcoRV&BamHI-Xhol) which

MLV. The experimental details for this strategy have been

was also digested with the same restriction enZymes, to obtain

previously set forth (Balasuriya et al., 2007; incorporated
herein by reference). Brie?y, the pTRSB plasmid sequence

the recombinant plasmid pEAVrVBSMLV(XhoI
EcoRV&BlnI-XhoI). Finally, in step 6, the fragment CD was

(McKnight et al., 1996) used in making in the virulent
pEAVrVBS infectious cDNA clone (Balasuriya et al., 2007;

25

cloned

into

the

plasmid

pEAVrVBSMLV(XhoI

EcoRV&BlnI-XhoI) which was also cut with the same

GenBank accession no. DQ846751) was used as the back
bone to construct the EAV MLV clone.

The viral RNA of EAV MLV strain (ARVAC®, Fort Dodge
Animal Health) was RT-PCR ampli?ed using four pairs of
synthetic oligonucleotide primers (a & b, c & d, e & f, and g

digested with restriction enZymes EcoRV and BlnI and then
restriction enZymes, to obtain the full-length clone

pEAVrMLV. Following assembly, the EAV MLV cDNA
30

(SEQ ID NO: 1) was immediately downstream of a T7 pro

moter for generation of full-length in vitro transcripts of EAV
MLV.

& h), designed according to the EAV MLV nucleotide
sequence (GenBank accession no. EU586275) to obtain four

EXAMPLE 2

overlapping fragments (termed AB, CD, EF, and GH). Long
PCR was carried out according to the manufacturers instruc

35

tions with the Expand Long Template PCR system (Boe
hringer Mannheim). The primers used are set forth in Table l .

Once assembly of the full-length clone was complete, its
authenticity was con?rmed by sequencing. That sequence is

TABLE 1
Primers used for reverse transcription and PCR
fragments AB, CD, EF and GH.

amplification of the EAV MLV (ARVAC)
Table l .

Primers for RT-PCR amplification of the

EAV MLV vaccine strain (ARVACC)

Digested
Primers for

with
restriction

Primers for PCR

Fragment reverse transcription Forward Primer

Reverse Primer

Fragment 5 ‘ GTCATCATCAGTGAG

Primer a

Primer b

AB

GATTAATACGACTCACT

CAGCGGCAGTGAT

GGCAG3 ‘

(SEQ ID NO:

5)

ATAGCTCGAAGTGTGTA GTAG3 ‘
TGGTG3 ‘
(SEQ ID NO:

enzymes
XbaI +
ECORV

'7)

(SEQ ID NO: 6)
Fragment 5 ‘ CCCCCGCGTTTGGTGA

Primer c

CD

5 ‘ TGCTTGTTCCATCTGG 5 ‘ TCTCCAGGTCTGT

ATGC3 ‘

(SEQ ID NO:

8)

Primer d

TCTG3 ‘

TTCAAGG3 ‘

(SEQ ID NO: 9)

(SEQ ID NO: 10)

Fragment S‘ACTTCTGTTGAGCTGA

Primer e

Primer f

EF

S‘ATTAGGAGCATTCTGG 5 ‘ACGCGACTCAGT

GGAG3 ‘

(SEQ ID NO:

11)

Fragment 5 ‘ GCACTCAGCTAGTAG
GH
ACATCCTCGAGTTTTTT
TTTTTTTTTTTTTTGGTT

CCTGGGTGGCTAATAAC
(SEQ ID NO: 14)

GCACC3 ‘

GTCTCAGG3 ‘

(SEQ ID NO: 12)

(SEQ ID NO: 13)

Primer g
Primer h
S‘TATTCTCGTCCGGTAGS ‘GCACTCAGCTAG
GTTCG3 ‘

(SEQ ID NO: 15)

TAGACATCCTCG3‘

(SEQ ID NO: 16)

EcoRV +
Blnl

Blnl +
BamHI

BamHI +
XhOI

US 8,012,735 B2
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set forth herein as SEQ ID NO: 1. The cloned virus sequence

prising SEQ ID NO:2 and including acceptable carriers,
including standard buffers, stabiliZers, diluents, preserva

(EAVrMLV) had 100% nucleotide identity to the master
sequence of the parental MLV vaccine strain (GenBank
accession no. EU586275).

tives, and the like, and may be formulated for extended
release. Adjuvants or other immunomodulators may be

included, such as Freund’s complete and incomplete adjuvant

EXAMPLE 3

and the like. An effective amount of vaccine can be deter

Plasmid containing the full-length sequence of the MLV
vaccine (pEAVrMLV; SEQ ID NO: 3; GenBank Accession

mined conventionally by methods knoWn to the skilled arti
san, such as administering sequentially increasing doses of
virus, plasmid, or vector comprising SEQ ID NO:1 and other

No. EJ798195) Was XhoI-lineariZed and in vitro transcribed

additives as described to ascertain proper dosages and any
side effects. Single or multiple administrations of vaccine are
contemplated. Immune response to the vaccine is monitored

(IVT) RNA Was generated for electroporation into baby ham
ster kidney cells (BHK 21 ; ATCC CCL10) according to pub
lished methods (Balasuriya et al., 1999). The electroporated
cells Were seeded onto culture plates and incubated at 370 C.
until complete cytopathic effect (CPE) Was observed to con
?rm infectivity. When 100% CPE Was observed the tissue

by conventional methods, such as seroconversion and anti
body titer post-vaccination. The presence of the marker vac
cine is detected by the presence of the unique restriction site

culture ?uid Was harvested and stored at —800 C.

Bsp EI (Example 5). This alloWs monitoring successful vac
cination, even in the presence of antibody to Wild-type Equine

EXAMPLE 4

The infectivity of the IVT RNA Was con?rmed also by
indirect immuno?uorescence (IFA; FIG. 2; see Balasuriya et

arteritis virus. Even more, it is possible to differentiate vac
20

mutation.
One of ordinary skill in the art Will recogniZe that addi
tional embodiments of the invention are also possible Without

al., 2007) to detect viral protein synthesis in BHK-21 cells
transfected With synthetic full-length RNA. Electroporated
cells Were plated directly onto chamber slides and incubated.
The cells Were labeled With anti-nsp1 monoclonal antibody

12A1 (Mab; FIG. 2b) and anti-nucleocapsid MAb 3E2 (FIG.

25

2d) at 24 hours post transfection. Mock-transfected cells Were
also stained With the same MAbs as controls (FIG. 211, 0).
EXAMPLE 5
30

To distinguish the cloned virus from the parental strain and
from other ?eld and laboratory EAV strains, a silent point
mutation (bp12,423 CQG) Was introduced into the cDNA
clone described in Example 1, providing another infectious
cDNA clone termed pEAVrMLVB (SEQ ID NO:4; GenBank
Accession No.: EJ798196). The silent point mutation Was

introduced using QuikChange II site-directed mutagenesis
kit (Stratagene) and the mutagenesis primers
EAV12423Pmut
(5'-GATGCGGGTCCGGAAACCGC
CCGCG-3': SEQ ID NO: 17) and EAV12423Nmut (5'
CGCGGGCGGTTTCCGGACCCATC-3': SEQ ID NO:18).

departing from the teachings herein. For example, the skilled
artisan Will appreciate that it is noW possible, using the
described cDNA clone of the modi?ed live virus of Equine
arteritis virus, to provide a validated repository of seed virus
for live virus vaccine production, ensuring a genetically
homogenous virus stock. Further, the clone ?nds utility in
development of mutations such as disable infectious single
cycle (DISC) mutant, alloWing a combination of the safety of

inactivated vaccines With the immunogenic activity of live
viral vaccines. Still further, the cDNA marker clone (SEQ ID
35

NO:4; Example 5) alloWs development of not only marker
vaccines (Example 7), but also diagnostic assays for differ
entiation of vaccinated animals from naturally infected ani
mals.

This detailed description, and particularly the speci?c
details of the exemplary embodiments, is given primarily for
40

This clone contained a unique restriction site Bsp El (5'
TCCGGA-3') at positions 12.419-12,424. This restriction site

is lacking in pEAVrMLV.
EXAMPLE 6

cinated animals (by the described marker vaccine) from
experimentally or naturally infected animals by detecting the

clarity of understanding, and no unnecessary limitations are
to be imported, for modi?cations Will become obvious to
those skilled in the art upon reading this disclosure and may
be made Without departing from the spirit or scope of the

invention. Relatively apparent modi?cations, of course,
45

A vaccine is formulated according to conventional meth

include combining the various features of one or more ?gures
or examples With the features of one or more of other ?gures
or examples.

ods, incorporating virus, plasmid, or other vectors comprising

SEQ ID NO:1 and including acceptable carriers, including
standard buffers, stabiliZers, diluents, preservatives, and the
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SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS:

1s

<211> LENGTH: 12704
<212> TYPE: DNA

<2l3> ORGANISM: Equine arteritis virus
<4oo> SEQUENCE:

1

gctcgaagtg tgtatggtgc catatacggc tcaccgccat atgcactgca agaattacta

6O

ttcttgtggg cccctctcgg taaatcctag agggctttcc tctcgttatt gcgagattcg

120

tcgttagata acggcaagtt ccctttctta ctatcctatt ttcatcttgt ggcttgacgg

180

gtcactgcca tcgtcgtcga tctctatcaa ctacccttgc gactatggca accttctccg

240

ctactggatt tggagggagt tttgttaggg actggtccct ggacttaccc gacgcttgtg

300

agcatggcgc gggattgtgc tgtgaagtgg acggctccac cttatgcgcc gagtgttttc

360

gcggttgcga aggagtggag caatgtcctg gcttgttcat gggactgtta aaactggctt

420

cgccagttcc agtgggacat aagttcctga ttggttggta tcgagctgcc aaagtcaccg

480

